Table 2. Doxorubicin-SQDG combination effect analysis.
| Combination |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| DOX (μM) | Cell viability % | Fa values for DOX | SQDG (μM) | Cell viability % | Fa values for SQDG | DOX (μM) | SQDG (μM) | Cell viability % | Fa values for combination | Combination index (CI) value |
| 0.2 | 91.8 ± 1.0 | 0.081 ± 0.010 | 5 | 86.4 ± 0.5 | 0.135 ± 0.005 | 0.2 | 5 | 38.9 ± 2.4 | 0.559 ± 0.009 | 0.513 ± 0.032 |
| 0.4 | 82.7 ± 2.3 | 0.173 ± 0.022 | 10 | 70.3 ± 2.8 | 0.296 ± 0.028 | 0.4 | 10 | 23.1 ± 6.1 | 0.768 ± 0.061 | 0.624 ± 0.130 |
| 0.6 | 72.3 ± 7.3 | 0.276 ± 0.073 | 15 | 48.6 ± 1.7 | 0.513 ± 0.017 | 0.6 | 15 | 12.1 ± 1.9 | 0.878 ± 0.018 | 0.627 ± 0.063 |
| 0.8 | 62.3 ± 7.5 | 0.406 ± 0.124 | 20 | 38.8 ± 0.9 | 0.611 ± 0.008 | 0.8 | 20 | 5.0 ± 2.2 | 0.949 ± 0.021 | 0.501 ± 0.104 |
| 1.0 | 46.2 ± 3.1 | 0.534 ± 0.025 | 25 | 23.9 ± 0.5 | 0.760 ± 0.005 | 1.0 | 25 | 2.0 ± 0.6 | 0.979 ± 0.005 | 0.393 ± 0.034 |
| 1.2 | 37.0 ± 2.6 | 0.629 ± 0.025 | 30 | 16.0 ± 0.3 | 0.839 ± 0.003 | 1.2 | 30 | 1.4 ± 0.3 | 0.985 ± 0.003 | 0.404 ± 0.007 |
| 1.4 | 24.1 ± 4.1 | 0.758 ± 0.040 | 35 | 10.3 ± 2.9 | 0.897 ± 0.028 | 1.4 | 35 | 0.1 ± 0.1 | 0.998 ± 0.005 | 0.136 ± 0.036 |
MOLT-4 cells were treated with either SQDG or doxorubicin or doxorubicin-SQDG constant ratio combinations and cell viability data were analyzed using CompuSyn Software. Values are presented as mean ± SD, for the three independent experiments. ‘DOX’ is abbreviation for doxorubicin.